Magnetic resonance imaging

Global Imaging CRO Market to Reach $9,603 Million by 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 15, 2021
Science, Health, Clinical Trials, Research, WuXi AppTec, Quality control, Syneos Health, Industry, PET, CRO, Service, ICON, CAGR, Modality, ICON plc, IXICO, Growth, Joint application design, Research, MRI, Cros, Biotechnology, Maintenance, Magnetic resonance imaging, Parexel, Positron emission tomography, Contract, Fine chemical, Medical imaging

Service - Imaging Acquisition and Protocol Development, Application Design, Image Collection and Quality Control, Digital Image Conversion, Support and Maintenance

Key Points: 
  • Service - Imaging Acquisition and Protocol Development, Application Design, Image Collection and Quality Control, Digital Image Conversion, Support and Maintenance
    Modality - Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Other Modalities
    Application - Oncology Imaging CRO, Ophthalmology Imaging CRO, Neurology Imaging CRO, Cardiology Imaging CRO, Other Applications
    End User - Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic and Government Research Institutes, Other End Users
    Key Questions Answered in this Report:
    What is the major factor driving the growth of the global imaging CRO market?
  • What are the different types of services offered in the global imaging CRO market?
  • What are the key development strategies implemented by the key players to stand out in this global imaging CRO market?
  • How have the strategic collaborations among the key players provided a large service sector within the global imaging CRO market?

RadSite Announces Complimentary Webinar Featuring 2021 Standards Development and Accreditation Updates

Retrieved on: 
Thursday, November 11, 2021
Volunteering, Herb Carneal, Accreditation, Leadership, CMS, Medicare, PET, Part Two, CEO, Medicare Improvements for Patients and Providers Act of 2008, Radiology, Cone beam computed tomography, Centers for Medicare & Medicaid Services, Research, Patient experience, Nuclear medicine, SPECT, MRI, Public policy, Patient, Magnetic resonance imaging, Awareness, ADI, MAP, Integration, Review, CT, Series, Medical imaging, Health insurance

ANNAPOLIS, Md., Nov. 11, 2021 /PRNewswire-PRWeb/ --RadSite, a leading accreditation organization promoting quality-based imaging practices, announced today the final details for its annual accreditation update webinar, which is part of its fall webinar series.

Key Points: 
  • ANNAPOLIS, Md., Nov. 11, 2021 /PRNewswire-PRWeb/ --RadSite, a leading accreditation organization promoting quality-based imaging practices, announced today the final details for its annual accreditation update webinar, which is part of its fall webinar series.
  • The complimentary webinar, " RadSite Standards and Accreditation Updates2021 Annual Update and What to Expect in 2022 ," will take place on November 17, 2021, 1:00 p.m. to 2:00 p.m.
  • The webinar will feature an overview and updates to RadSite's MIPPA Accreditation Program Standards and Guide, including the new specialty accreditation modules.
  • The webinar will feature David J. Waldron, CEO of Traction Business Development LLC, and Mark Casner, RadSite Accreditation Committee Chair.

Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
Cav2.1, Seizure, Clinical trial, Depression, Security (finance), Nerve block, Food, Securities Exchange Act of 1934, COVID-19, Flunarizine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, XEN402, Therapy, Anhedonia, Foot, Drug Quality and Security Act, EPIK, Webcast, Fast Track, Safety, Adolescence, Epilepsy, Method, Research, Securities Act of 1933, U.S. Securities and Exchange Commission, Icahn School of Medicine at Mount Sinai, Time, Patient, FDA, Adult, Orphan, Private Securities Litigation Reform Act, Mount Sinai, Investor, KCNQ2, MDD, European Commission, Income, Nerve, Sale, SCN8A, Magnetic resonance imaging, Magnetic resonance, Neurocrine Biosciences, Ageing, Idiopathic generalized epilepsy, Lists of diseases, KCNQ, CNS, Reward, Royal commission, IND, Pharmaceutical industry

BURNABY, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • For the quarter ended September 30, 2021, Xenon reported total revenue of $8.1 million, compared to $6.6 million for the same period in 2020.
  • Net loss for the quarter ended September 30, 2021 was $15.4 million, compared to $8.9 million for the same period in 2020.
  • Xenon will host a conference call and live audio webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the third quarter results and provide a corporate update.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Airrosti and Luna Partner to Improve Access for Musculoskeletal Care

Retrieved on: 
Wednesday, November 10, 2021
Quality of life, MSK, SAN, Magnetic resonance imaging, Geography, Physical, Partnership, Pain, ARR, Time, Motion, Patient, Head, District, Therapy, Documentation, Healthcare, Medicine

Using Luna's in-person, on-demand physical therapy services platform, Airrosti can immediately expand access to convenient, high-quality, at-home care for patients in the 46 states currently covered by ARR.

Key Points: 
  • Using Luna's in-person, on-demand physical therapy services platform, Airrosti can immediately expand access to convenient, high-quality, at-home care for patients in the 46 states currently covered by ARR.
  • For these patients and in markets where Airrosti doesn't have clinics, the Airrosti and Luna partnership is particularly important.
  • "This alliance with Luna provides timely and efficient access to high-quality care that improves clinical efficacy and drives better outcomes.
  • Airrosti Rehab Centers (Airrosti), is a national health care group that employs and trains skilled providers who specialize in delivering high-quality, outcome-based musculoskeletal care, both in person and virtually through their digital healthcare solution, Airrosti Remote Recovery (ARR).

NEXPLANON® (etonogestrel extended-release subdermal implant) Now Covered by Quebec's Public Formulary

Retrieved on: 
Monday, November 8, 2021
MSD, Coronavirus, Private Securities Litigation Reform Act, Pregnancy, News, Health, Health Canada, OGN, Method, Security (finance), Arm, MRK, STI, Veterans Affairs Canada, Investment, Internal bleeding, COVID-19, Condom, MRI, USS, Woman, U.S. Securities and Exchange Commission, Magnetic resonance imaging, SEC, NYSE, Physician, Subdermal implant, Patient, CT, Patent, RAMQ, Non-Insured Health Benefits, Birth control, Pharmaceutical industry

KIRKLAND, QC, Nov. 8, 2021 /CNW/ - Organon (NYSE: OGN) is pleased to announce NEXPLANON (etonogestrel extended-release subdermal implant) public listing in Quebec under the Rgie de l'assurance maladie du Qubec (RAMQ) as of November 10.

Key Points: 
  • KIRKLAND, QC, Nov. 8, 2021 /CNW/ - Organon (NYSE: OGN) is pleased to announce NEXPLANON (etonogestrel extended-release subdermal implant) public listing in Quebec under the Rgie de l'assurance maladie du Qubec (RAMQ) as of November 10.
  • NEXPLANON is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1Quebec is the fifth jurisdiction to list NEXPLANON on its public formulary, including the Non-Insured Health Benefits program, Veterans Affairs Canada and the Saskatchewan Drug Plan.
  • "Choosing a contraception method is an incredibly personal decision based on what's best for your body and your needs.
  • The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH

Retrieved on: 
Thursday, November 4, 2021
Magnetic resonance imaging, Preterm birth, Metabolic syndrome, Form 8-K, New Drug Application, Cirrhosis, NAFLD, Obesity, Fast Track, White Light Rock & Roll Review, Patient, Private Securities Litigation Reform Act, FDA, Liver injury, Cardiovascular disease, SALT, Food, Fast track (FDA), Biopsy, XR, SEC, Adipose tissue, Insulin resistance, Review, Risk, Hypogonadism, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Non-alcoholic fatty liver disease, Adult, Trial of the century, Multimedia, Man, NDA, Form 10-K, Diabetes, NASH, Testosterone, Lift, Population, Hydroxyprogesterone caproate, Pharmaceutical industry

SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ --Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders,today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to LPCN 1144 as a treatment for non-cirrhotic non-alcoholic steatohepatitis ("NASH").

Key Points: 
  • SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ --Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders,today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to LPCN 1144 as a treatment for non-cirrhotic non-alcoholic steatohepatitis ("NASH").
  • "The granting of Fast Track Designation represents an important recognition bythe FDAof LPCN 1144's potential to address a significant unmet need in the treatment of NASH," said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine.
  • "We believe the Fast Track Designation will enable us to work closely with the FDA on our development program for NASH, including the design of the Phase 3 program."
  • Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107.

Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 3, 2021
Safety, Fibrosis, Magnetic resonance imaging, EASL, Human, Hypercholesterolemia, The Obesity Society, Lipid, SAN, GIP, Disease, Adrenoleukodystrophy, Triglyceride, Obesity, X-ALD, Patient, Trial of the century, NASDAQ, AMN, Vital signs, Review, Quarter, Adult, Male, Program, Pharmacokinetics, Non-alcoholic fatty liver disease, Fatty liver disease, Therapy, NASH, Half-life, Risk, Population, Lists of diseases, Neurodegeneration, Plasma, Pharmaceutical industry

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments.

Key Points: 
  • SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments.
  • Viking ended the third quarter of 2021 with approximately $216 million in cash, cash equivalents and short-term investments.
  • Management will host a conference call to discuss the company's third quarter 2021 financial results today at 4:30 pm Eastern.
  • This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S.

AMRA Medical's AASLD Presentations - A Body Composition Research Quartet

Retrieved on: 
Wednesday, November 3, 2021
MRI, Magnetic resonance imaging, Transplant, Phenotype, Research, AASLD, 2021 Essex County Council election, Association, Institute of Liver and Biliary Sciences, NAFLD, American Association for the Study of Liver Diseases, Adipose tissue, Time, The X Factor Digital Experience, Conference, Precision medicine, Liver disease, CHD, Biomarker, Moyamoya disease, Multimedia, American Association, Mortality, Body composition, Medical imaging, Dietary supplement

Specifically, four abstracts have been accepted for poster presentation, which will be presented by an AMRA team member or research collaborator.

Key Points: 
  • Specifically, four abstracts have been accepted for poster presentation, which will be presented by an AMRA team member or research collaborator.
  • AMRA researchers used MRI to assess muscle and fat volumes in individuals with NAFLD.
  • They found that muscle biomarkers describing muscle composition (muscle volume and fat infiltration) were associated with all-cause mortality in individuals with NAFLD.
  • By attending AMRA's presentations, researchers and clinicians can learn about the strengthened evidence for muscle composition measurements as important biomarkers in early and late stages of liver disease.

Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Retrieved on: 
Wednesday, November 3, 2021
MRI, Dementia, Tau, Disease, Failure, Pathology, Twitter, Multiple sclerosis, Nausea, Climate, Clinical trial, COVID-19, AD, Health, Acquisition, GLOBE, Prevalence, Medication, Research, Diagnosis, ARIA, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Confusion, Spinal muscular atrophy, Nobel Prize, Brain, Allergy, Bleeding, Intellectual property, BIIB, Science, Magnetic resonance imaging, PRIME, Biotechnology, HIV disease progression rates, Dizziness, Drug development, Lists of diseases, Risk, Social media, EMERGE, News, Nasdaq, Population, Patient, NACC, Plasma, LinkedIn, Jonas Gustavsson, Gustafson, Frontotemporal dementia, TANGO, Headache, YouTube, Data, National, Neuroscience, Pharmacokinetics, EST, Alzheimer's disease, Swelling, Medical imaging, Pharmaceutical industry

Additional phase 3b late breaker data will shed light on clinical decline and amyloid beta plaque levels after patients stopped treatment.

Key Points: 
  • Additional phase 3b late breaker data will shed light on clinical decline and amyloid beta plaque levels after patients stopped treatment.
  • With data from the largest clinical trial dataset in early Alzheimers disease, Biogen contributes 11 presentations to CTAD, supporting robust scientific insights and dialogue.
  • Biogens contributions to the conference are driven in part by analyses from the largest clinical trial dataset in early Alzheimers disease research.
  • The accumulation of amyloid beta plaques and tangles of tau proteins in brain cells are the two defining pathologies of Alzheimers disease.

IronMatt Acknowledged for Funding Groundbreaking Research

Retrieved on: 
Tuesday, November 2, 2021
Children, Health, Philanthropy, Pharmaceutical, Oncology, Research, Family, Surgery, Foundation, Consumer, Science, MRI, Research, Brain, Technology, Memorial Sloan Kettering Cancer Center, Journal of Neurosurgery, Diffuse intrinsic pontine glioma, PET, CED, THE, Patient, MATTHEW, DIPG, Software, Magnetic resonance imaging, Board, Pediatrics, Awareness, Investor, Journal, Board of directors, Medical imaging, Medical device

The mission of IronMatt is to help children and families affected by pediatric brain tumors through awareness, research and financial support.

Key Points: 
  • The mission of IronMatt is to help children and families affected by pediatric brain tumors through awareness, research and financial support.
  • IronMatt was a key supporter of this research project led by nationally recognized pediatric neurosurgeon, Dr. Mark Souweidane, and his team of five colleagues.
  • This project was conducted at Memorial Sloan Kettering Cancer Center and ten pediatric patients were treated at the same dose level.
  • The ten pediatric patients included six females and four males, with an age range of 3 to 11 years old.